Kornimate/medical-research-clean huggingface dataset:
digital vs analog impression in cases of all-on-4 - prosthesis

Conditions: Edentulous Mouth

Summary: fifty six patients were randomly enrolled in the study. participants were randomly stratified into two control groups and two test groups, from which conventional pick up and digital impressions were made respectively. patients of group 1 (cig axial) and 3 (dig axial) received 4 axial implants whereas, group 2 patients (cig tilted), and group 4 (dig tilted) received two anterior axial implants and two distal tilted implants. all participants received hybrid dentures. bone loss, implant loss, maintenance of prosthesis were evaluated at 6m,12m, and 24 months follow up period.


Eligibility criteria:
inclusion criteria: * completely edentulous patients with age range from 50-65 years. * physically and psychologically eligible participants for implants placement. * adequate bone to receive 4 interforaminal implants. exclusion criteria: participants were excluded if * medical conditions that precludes implants placement * smokers * patients suffering from any parafunctional habits

Keywords: impressions analogue digital all-on-four
evaluation of the association between genetic load and response to anti-vegf therapy in amd patients

Conditions: Age Related Macular Degeneration

Summary: patients with amd who are being or have been treated with eye injections of drugs known as anti-vegf agents with either good or poor response will have dna collected with check swabs for analysis.

the study is designed as a single-center, observational case control evaluation to compare the genetic profiles of two groups of patients categorized according to anti-vegf treatment response as either "positive" or "suboptimal" responders following treatment with either bevacizumab or ranibizumab anti-vegf agents. positive and suboptimal responders will be compared to determine if genetic variant distribution or total genetic load is associated with anti-vegf treatment response.

Eligibility criteria:
inclusion criteria: * subject is male or female 55 years of age and older * subject is self-reported as non-hispanic caucasian * subject provides a signed and dated informed consent * subject agrees to provide two buccal swabs in accordance with this protocol * diagnosis of cnv secondary to amd in at least one eye * subject satisfies one of the following: 1. has received at least one injection of anti-vegf therapy (bevacizumab or ranibizumab) with no evidence of residual subretinal or intra-retinal fluid present on sdoct one month (+/- 1 week) following most recent injection; or 2. has received three or more injections in last six months with residual subretinal or intra-retinal fluid present on sdoct one month (+/- 1 week) following most recent injection, has not shown complete resolution of fluid following any injection in last 6 months, and shows leakage on fa or icg imaging at some time during last 12 months. exclusion criteria: * previous sample donation under this protocol * presence of retinal disease involving the photoreceptors and/or outer retinal layers other than amd loss such as high myopia, retinal dystrophies, central serous retinopathy, vein occlusion, diabetic retinopathy and uveitis or similar outer retinal diseases which have been present prior to the age of 50. * opacities of the ocular media, limitations of pupillary dilation or other problems sufficient to preclude adequate imaging of the posterior segment.

Keywords: age related macular degeneration choroidal neovascular anti-vegf therapy
efficacy of cc-5013 (revlimid or lenalidomide) in patients with primary systemic amyloidosis

Conditions: Amyloidosis

Summary: patients with primary systemic amyloidosis will be treated with cc-5013 (lenalidomide; revlimid) as a single agent for 3 months. if their disease worsens or does not improve during that time frame dexamethasone will be added to the treatment program.


Eligibility criteria:
1. histochemical diagnosis of amyloidosis as based on detection by polarizing microscopy of green birefringent material in congo red-stained tissue specimens and immunohistochemical proof of al 2. measurable disease of al amyloidosis as defined by one of the following: * serum monoclonal protein \>=1.0 g by protein electrophoresis * \>200 mg of monoclonal protein in the urine on 24 hour electrophoresis * serum immunoglobulin free light chain \& \>=10 mg/dl and abnormal serum immunoglobulin kappa to lambda free light chain ratio 3. ecog performance status (ps) 0, 1, 2, or 3 4. \>=18 years of age 5. the following laboratory values obtained \<=14 days prior to registration: * creatinine \< = 3 mg/dl * absolute neutrophil count \>=1000/microliter * platelet \>=75000/microliter * hemoglobin \> = 8.0 g/dl 6. symptomatic organ involvement with amyloid to justify therapy. this could include liver involvement, cardiac involvement, renal involvement, peripheral neuropathy grade 1, or soft tissue involvement. must have more than purpura or carpal tunnel syndrome 7. previously treated or untreated. no limit to prior therapy provided there is adequate residual organ function 8. ability to provide informed consent 9. anticipated life expectancy of at least 3 months 10. none of the following: * pregnant women or women of reproductive ability who are unwilling to use effective contraception * nursing women * men who are unwilling to use a condom (even if they have undergone a prior vasectomy) while having intercourse with any woman, while taking the drug and for 4 weeks after stopping treatment * myelosuppressive chemotherapy \< 4 weeks prior to registration * concomitant high dose corticosteroids * grade 2 (or higher) peripheral neuropathy * uncontrolled infection * clinically overt multiple myeloma * active malignancy * prior hypersensitivity reaction to thalidomide * syncope within the past 30 days
the analysis of thyroidectomy and parathyroidectomy

Conditions: Thyroid Diseases; Parathyroid Diseases

Summary: to analyze surgery or not, different surgical methods, timing of surgery, and alternative managements for patients of thyroid or parathyroid disease.

utilizing our institutional database, tissue bank, and electronic medical charts to surgery or not, different surgical methods, timing of surgery, and alternative managements for patients of thyroid or parathyroid disease.

Eligibility criteria:
inclusion criteria: * age more than 20 years * thyroid or parathyroid disorder * willing to receive management at national taiwan university hospital (ntuh) exclusion criteria: * age less than 20 years

Keywords: surgery ablation minimal invasive surgery
integrated clinical evaluation of traditional chinese medicine (tcm) and conventional medicine on diabetic patients

Conditions: Diabetes Mellitus

Summary: in traditional chinese medicine (tcm), examination of the tongue plays an important role in diagnosis. the characteristics of the tongue(e.g., color of the tongue body, tongue fur, teeth-marked tongue) provides some clues and prognosis, which are considered a reflection of the body's internal condition. diabetes mellitus is a metabolic disorder of hyperglycemia, which lead to damage the kidneys, eyes, nerves, blood vessels, and heart. long standing hyperglycemia can also be associated with buccal alteration. the purpose of this study was to survey on tongue diagnosis and other examinations associated with diabetic mellitus.


Eligibility criteria:
inclusion criteria: * diabetic patients(ac sugar\>126mg/dl or hba1c\>6.5, twice) * pre-diabetic patients(100mg/dl \<ac sugar\<126mg/dl, or 5.9\<hba1c\<6.5) * non-diabetic patients(ac sugar\<100mg/dl ) exclusion criteria: * acute infectious disease, * cancer, * end stage renal disease

Keywords: tongue diagnosis heart rate variability nailfold videocapillaroscopy
study on the relationship between neutrophil-mediated thrombocytopenia and the condition and the course of disease in patients with hfrs

Conditions: Hemorrhagic Fever With Renal Syndrome

Summary: thrombocytopenia is an important pathological feature of hfrs（hemorrhagic fever with renal syndrome, hfrs）. however, the cause of thrombocytopenia in hfrs is not yet fully understood. neutrophils, as the largest number of white blood cells in the human body, can widely participate in the immune process of viral infections. previous studies have found that the neutrophils of patients with acute myocardial infarction can interact with activated platelets and further mediate platelet phagocytosis.therefore, this study aims to systematically elucidate the immunological process of neutrophil mediated thrombocytopenia in patients with hfrs by exploring the correlation between platelet activation, neutrophil activation and neutrophil proportion of adherent / phagocytic platelets peripheral blood of hfrs patients, and to analyze its relationship with the course of hfrs disease, which lays a theoretical foundation for further understanding the pathogenesis of hfrs and provides a basis for clinical use.


Eligibility criteria:
inclusion criteria: * age ≥18 years; * clinical diagnosis meets the diagnostic criteria of the national hfrs prevention and treatment plan (hantavirus-specific igm antibody is positive). the classification and staging standards of hfrs patients are based on the "expert consensus of shaanxi province on diagnosis and treatment of hemorrhagic fever with renal syndrome". exclusion criteria: * age \<18 years; * have a history of kidney disease; * have a history of liver disease; * have a history of malignant tumor; * receive dialysis treatment before admission; * combined with hypertension, coronary heart disease and diabetes history; * combined with hiv infection and patients with autoimmune diseases and pregnancy.
pharmacokinetics and safety of sancuso and iv granisetron in pediatrics aged 6 to 12 years

Conditions: Chemotherapy Induced Nausea and Vomiting

Summary: the purpose of this study is to determine the dosing strategy for adolescents aged 6 to 12 years.

this is an open-label, multi-center, cross-over study in male and female pediatric cancer patients, aged 6 to 12 years of age who are receiving at least 2 cycles of emetogenic chemotherapy requiring 5-ht3 antagonist treatment of up to 5 days duration. the study is designed to evaluate the safety and pk of transdermal granisetron (sancuso® patch) in a pediatric population (aged 6 to 12 years), using a population pk approach.

Eligibility criteria:
inclusion criteria: 1. 6 to 12 years of age inclusive at screening. 2. written patient or parental (or appropriate legal representative) irb approved informed consent as appropriate. 3. written patient assent (as appropriate). 4. confirmed malignancy. 5. scheduled to receive 2 or more cycles\* of emetogenic chemotherapy requiring 5-ht3 antagonist treatment. 6. scheduled to receive one or more consecutive days of 5-ht3 antagonist treatment, per cycle, as cinv prophylaxis. * the cycles of chemotherapy must be consecutive (i.e. one followed by the other) but do not have to be the first and second cycle of a line of treatment. exclusion criteria: 1. hypersensitivities, allergies or contraindications to study medications; intolerance of medical tape or sticking plaster. 2. clinical or laboratory signs and symptoms of significant cerebral, cardiovascular, respiratory, renal, hepatobiliary, pancreatic or infectious disease, which in the investigator's judgment may interfere with the study assessment or completion of the study. 3. patients with a known history or predisposition to cardiac conduction interval abnormalities, including qt syndrome, or known family history of long qt syndrome or taking medications that are known to prolong the qt interval. 4. patients scheduled to have routine surgery during the study duration. 5. patients with a life expectancy of \< 6 months. 6. scarring or significant skin disease on both upper arms. 7. female patients who are pregnant or breast-feeding. all post menarche female patients must have a pregnancy test at screening. 8. patients who are known or thought to be sexually active must use effective birth control.\*\* 9. administration of other investigational drugs within 30 days preceding the screening visit, except for anticancer treatments. 10. any conditions associated with non-compliance. * effective birth control includes absolute abstinence or double barrier birth control methods i.e. condom and one of the following: combined oral contraceptive, diaphragm, depot contraceptive injection.

Keywords: cinv
dobutamine for management of surgical patients with septic shock

Conditions: Patients with Septic Shock; Surgical Patients; General Anesthesia

Summary: septic shock is the last and most severe stage of sepsis and is defined by extremely low blood pressure, despite lots of intravenous fluids. the incidence of septic shock related cardiomyopathy was 10% to 70%. besides, general anesthesia will inhibit the sympathetic nervous system, reduce myocardial contractility and aggravate cardiac dysfunction. no randomized controlled trials have yet explore the effects of dobutamine on clinical outcomes for patients with septic shock undergoing surgery under general anesthesia.

sepsis, defined as life-threatening organ dysfunction, is caused by a dysregulated host response to infection, which 30-day mortality rate is about 24.4%. septic shock is the last and most severe stage of sepsis and is defined by extremely low blood pressure, despite lots of intravenous fluids. surgical patients with septic shock are not rare. the incidence of septic shock related cardiomyopathy was 10% to 70%. besides, general anesthesia will inhibit the sympathetic nervous system, reduce myocardial contractility and aggravate cardiac dysfunction, furthermore exacerbate hemodynamic instability, and then increase the incidence of aki and patient mortality. therefore, to improve cardiac function in patients with septic shock who received general anesthesia is the key to save patients life and improve prognosis. the latest international guidelines for the treatment of septic shock recommend - in patients with septic shock combined with cardiac dysfunction, treatment with norepinephrine in combination with dobutamine is recommended if inadequate tissue perfusion persists after adequate fluid resuscitation and maintenance of blood pressure, but the level of evidence is weak. dobutamine acts on β-adrenergic receptors, which can improve tissue perfusion, and small doses of 2.5-5ug/kg/min can increase myocardial contractility and improve cardiac function in patients without increasing heart rate. previous study has demonstrated that the combined use of norepinephrine and dobutamine can elevate left ventricular ejection fraction, cardiac index, improve tissue perfusion, and reduce mortality in patients with septic shock. no randomized controlled trials have yet explore the effects of dobutamine on clinical outcomes for patients with septic shock undergoing surgery under general anesthesia.

Eligibility criteria:
inclusion criteria: 1. patients with 18 years or older 2. sugery patients with septic shock and the duration of opration is more than 1 hour exclusion criteria: 1. pregnancy; 2. long-term intakeβ-receptor blocker; 3. patietns with dobutamine used within 72h before enrollment; 4. patients use recombinant human brain natriuretic peptide(rhbnp), levosimendan and epinephrine within 72h before enrollment; 5. patients with hyperthyroidism; 6. allergy or known sensitivity to catecholamines（norepinephrine, dobutamine etc.）and genera anesthetics. 7. patients and guardians refused to participate in this intervention clinical trial.
juvenile essential arterial hypertension and vascular function

Conditions: Child, Only; Essential Hypertension

Summary: the main goal of this study is to investigate the association of the juvenile essential arterial hypertension with systemic micro- and macrovascular reactivity and cerebral vascular function, and to examine the potential impact of elevated oxidative stress on this associations.


Eligibility criteria:
inclusion criteria: * healthy normotensive children and children with essential arterial hypertension exclusion criteria: * secondary arterial hypertension * other systemic diseases with immunopathology * neurodegenerative diseasesat * children that use therapy which has a high impact on vascular or immunological function (immunotherapy, immunosuppressive therapy, sistemic corticosteroid therapy etc..).

Keywords: cerebral circulation child endothelium microcirculation macrocirculation hypertension oxidative stress
prevention of injuries in young athletics (track and field) athletes

Conditions: Sports Injury

Summary: the long-term purpose of an on-going participatory action research program "the klub-study" in sweden, that involves scientists and representatives from all levels of athletics, is to develop a sustainable framework for safe athletics (track and field) training for child athletes born 2002-2006. the first part of the research program, a 1-year longitudinal study analysing training and injury data, was completed in november 2017. the present study sets out to evaluate a website that aims to support coaches and caregivers in their role as adult key stakeholders to foster young athletes to become adult athletes who possess the tools to maintain a healthy sporting lifestyle.

the intervention will be implemented in youth athletics and evaluated in a randomised controlled trial (rct). it will follow the consensus guidelines for studies in athletics and be reported according to the consort checklist. the participating clubs will be randomly allocated into active and control group. the active group will be provided the intervention program, i.e. access to a website, aimed to support coaches, caregivers´ and athletes' and improve knowledge and health literacy to make more informed choices that promote health. the control group will continue to train according to their routines and will get access to the website after 4 months. the participants will be assessed at three times, at the beginning of the study (t1), after four months (t2), at ten months (t3) and additional prospective data on training and injury will be collected during the first four months (t1b).

Eligibility criteria:
inclusion criteria: * belonging to a sports club and participate in organized training, athletics (track and field) * born 2002 - 2006 exclusion criteria: * not, on a regular basis, participating in athletics (track and field) training
effect of mechanical vestibular stimulation on hand function in hemiparetic children

Conditions: Cerebral Palsy

Summary: the current study will be directed to determine the effect of mechanical vestibular stimulation on fine motor skills and pinch strength in children with hemiparesis. hemiplegic cerebral palsy causes problems with contraction, sensation, and muscular strength in the upper limbs, and its effective use of muscles for reaching, grasping, releasing, and manipulating objects is often compromised


Eligibility criteria:
inclusion criteria: * children will be included in the study if they fulfil the following criteria: 1. diagnosed with hemiparetic cerebral palsy. 2. age ranged from 4 to 6 years. 3. children with spasticity grades ranged from 1 to 1+ according to modified ashworth scale 4. both genders will be included. 5. the child will be able to follow verbal commands and instructions. exclusion criteria: * children will be excluded from the study if: 1. any congenital or developmental disorders in addition to hemiplegia cerebral palsy. 2. current hospitalization for urgent medical reasons. 3. severe mental retardation. 4. children having visual or auditory defects. 5. children who had botox application to the upper extremity in the past 6 months or had undergone a previous surgical intervention to the wrist and hand.
assessment of clinically related outcomes and biomarker analysis for translational integration in colorectal cancer

Conditions: Colorectal Cancer

Summary: * a prospective, observational study on clinical outcomes of surgical management of primary and metastatic colorectal cancer * prospective collection of tissues to explore potential biomarkers in blood and/or primary or secondary cancers and/or normal colon

prospective project in collecting and assessing clinical outcomes data related to molecular profiling of tumors based on cancer primary or metastatic tissue or tissue from peripheral blood samples. as a future part of the project will be collected patient reported outcomes (pros) for assessing clinical outcomes in relation to clinical pathways, patient reported results, as well as tumor profiling by molecular methods.

Eligibility criteria:
inclusion criteria: * diagnosis of colorectal cancer, primary or metastatic (liver), with a treatment intention of planned curative surgery * informed consent to participate * age ≥18 exclusion criteria: * failure to provide written informed consent

Keywords: colon cancer rectal cancer liver metastasis survival biomarker molecular profile
time of exercise re-training with chronic obstructive pulmonary disease (copd)

Conditions: Respiratory Diseases

Summary: pulmonary rehabilitation (pr) is an effective intervention for reducing hospital readmissions, secondary events, and mortality in patients with respiratory pathologies. the program should not be improved by introducing new subjects such as circadian rhythm.

respiratory diseases are a leading cause of death in developed countries. to avoid complications and recurrences, secondary prevention in patients with respiratory diseases is essential. pulmonary rehabilitation (pr) is a well-established and effective treatment that is supervised by medical professionals and conducted in dedicated centres. it has been shown to reduce hospital readmissions, secondary events, and patient mortality. the timing of reconditioning is crucial. previous studies have indicated that training times affect strength and power gains. additionally, the time of day for training can significantly impact progress in aerobic capacity. disturbances to the biological clock can have consequences for people with respiratory pathologies, particularly an alteration in muscular function. therefore, studying the temporal specificity of exercise re-training in patients with respiratory diseases is of interest.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * patient with chronic obstructive pulmonary disease (copd) * registered for respiratory re-education and rehabilitation at the clinique de la mitterie * number of rehabilitation sessions at least 18 over 4 weeks * written informed consent signed by the patient * membership of a social security exclusion criteria: * - cardiovascular contraindications to exercise * unstable respiratory status (uncompensated respiratory acidosis) * conditions interfering with the pulmonary rehabilitation process (progressive neuromuscular disease, psychiatric illness)

Keywords: respiratory diseases pulmonary rehabilitation chronic obstructive pulmonary disease biological clock